Large scale, prospective screening of EGFR mutations in the blood of advanced NSCLC patients to guide treatment decisions

Autor: Ariadna Balada-Bel, Nuria Viñolas, Mónica Garzón-Ibáñez, Rafael Rosell, S. Calabuig, Carlos Camps, Irene Moya-Horno, Núria Jordana-Ariza, A.K. Santos-Rodríguez, Niki Karachaliou, D. Aguiar, Daniela Morales-Espinosa, Ana Pérez-Rosado, Maria José Catalán, Maria Gonzalez-Cao, Maria-de-los-Llanos Gil, Raquel Campos, Xavier Gonzalez, Santiago Viteri-Ramirez, Beatriz García-Peláez, J.C. Monasterio, M.A. Molina-Vila, M.A. Muñoz-Quintana, Jordi Bertran-Alamillo, Margarita Majem, Alejandro Martinez-Bueno, J. Remon-Massip, Sergi Villatoro, E. Jantus, P. Lianes-Barragan, A.E. Sosa, Clara Mayo-de-las-Casas, Noemí Reguart, E. Ovalle

Publikováno v: ANNALS OF ONCOLOGY
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Annals of Oncology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol

Background: In a significant percentage of advanced non-small-cell lung cancer (NSCLC) patients, tumor tissue is unavailable or insufficient for genetic analyses. We prospectively analyzed if circulating-free DNA (cfDNA) purified from blood can be us

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55e199397fe7294403b7b4c58788366a
https://pubmed.ncbi.nlm.nih.gov/28911086